ALS Untangled says Protandim warrants further study despite limited evidence
Original source
Protandim (opens in a new tab)ALS Untangled reviewed Protandim, a supplement proposed for amyotrophic lateral sclerosis (ALS). The review described a potentially useful mechanism and one patient with a validated ALS diagnosis whose ALSFRS-R score improved while taking it. It also identified major gaps in the evidence.
Why this matters
The review suggests that Protandim may be worth studying, but it does not show that the supplement benefits people with ALS or change treatment recommendations. People considering it should note that the evidence described is limited and includes unresolved questions about dose, biological effects and possible conflicts of interest.
Limitations and context
This is an independent expert review, not a new clinical trial or primary research report. The review cites small samples, no demonstration that Protandim increases Nrf2 in humans, no established optimal dose and potential conflicts of interest involving several key individuals. The reported improvement in one patient cannot establish effectiveness.